Autres langues Lyell Immunopharma, Inc.

Actions

LYEL

US55083R1041

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/04/2024			Varia. 5j.	Varia. 1 janv.
2,38 ^USD	-1,24 %		-2,86 %	+22,68 %

28/02	Lyell Immunopharma, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
28/02	Lyell Immunopharma, Inc. annonce ses résultats pour le quatrième trimestre clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting	05/03
North American Morning Briefing : Stock Futures -2-	04/03
Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q4 Revenue $13,000	28/02
Lyell Immunopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023	28/02
Lyell Immunopharma Announces Participation in March Investor Conferences	26/02
Lyell Immunopharma Announces Participation in March Investor Conferences	26/02
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc.	14/02
MaxCyte's strategic platform licences redeem otherwise modest results	09/01
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference	03/01
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) dropped from S&P Biotechnology Select Industry Index	18/12
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma	09/11
Lyell Immunopharma: Q3 Earnings Snapshot	07/11
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Posts Q3 Revenue $25,000	07/11
Lyell Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023	07/11
SITC 2023: Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors	04/11
SITC 2023: Epi-R P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture time	03/11
SITC 2023: Rejuvenation of tumor-infiltrating lymphocytes (TIL) through Partial Reprogramming	03/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lyell Immunopharma, Inc.

Actions

LYEL

US55083R1041

Autres langues

Filtres